Not all tumor cells express PD-L1; therefore, it is necessary to evaluate the levels of PD-L1 in tumor cells using immunohistochemistry (IHC) or other pathological methods before treating patients with targeted inhibitors of PD-L1. This evidence concerns the gene CD274 and neoplasm.